Genetic alterations of histone lysine methyltransferases and their significance in breast cancer

Oncotarget

Volumn 6, Issue 4, 2015, Pages 2466-2482

  Liu, Lanxin ^a   Kimball, Sarah ^a   Liu, Hui ^a   Holowatyj, Andreana ^a   Yang, Zeng Quan ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Deletion; Gene amplification; Histone lysine methyltransferase; Mutation

Indexed keywords

HISTONE LYSINE METHYLTRANSFERASE; MESSENGER RNA; ISOENZYME;

ARTICLE; ASH1L GENE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 1Q; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DRUG TARGETING; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HMT GENE; HOMOZYGOSITY; HUMAN; HUMAN CELL; KMT2C GENE; KMT2D GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SETDB1 GENE; SETDB2 GENE; SMYD2 GENE; SMYD3 GENE; SOMATIC MUTATION; SUV420H1 GENE; WHSC1L1 GENE; BREAST TUMOR; CLASSIFICATION; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETICS; KAPLAN MEIER METHOD; META ANALYSIS; METABOLISM; MUTATION; PATHOLOGY; PHYLOGENY; PROGNOSIS; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; ISOENZYMES; KAPLAN-MEIER ESTIMATE; MUTATION; PHYLOGENY; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84923066119     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2967     Document Type: Article

References (58)

1. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-536.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad SciUSA. 2001; 98(19):10869-10874.
3. Reis-Filho JS and Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011; 378(9805):1812-1823.
4. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics: Targets & Therapy. 2012; 6:289-297.
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21):2492-2502.
6. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70.
7. Greer EL and Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012; 13(5):343-357.
8. Albert M and Helin K. Histone methyltransferases in cancer. Semin Cell Developmental Biol. 2010; 21(2):209-220.
9. Herz HM, Garruss A and Shilatifard A. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem Sci. 2013; 38(12):621-639.
10. Roy DM, Walsh LA and Chan TA. Driver mutations of cancer epigenomes. Protein Cell. 2014; 5(4):265-296.
11. Shen H and Laird PW. Interplay between the Cancer Genome and Epigenome. Cell. 2013; 153(1):38-55.
12. Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN and Ethier SP. Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res. 2010; 70(21):8487-8497.
13. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad SciUSA. 2003; 100(20):11606-11611.
14. Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R and Cristofanilli M. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res: CR. 2013; 32:70.
15. Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P and Zi X. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets. 2013; 13(5):558-579.
16. Albertson DG. Gene amplification in cancer. Trends Genet. 2006; 22(8):447-455.
17. Albertson DG, Collins C, McCormick F and Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003; 34(4):369-376.
18. Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun YC, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signaling. 2013; 6(269).
19. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery. 2012; 2(5):401-404.
20. Liu L, Zhen XT, Denton E, Marsden BD and Schapira M. ChromoHub: a data hub for navigators of chromatin-mediated signalling. Bioinformatics. 2012; 28(16):2205-2206.
21. Yang ZQ, Streicher KL, Ray ME, Abrams J and Ethier SP. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res. 2006; 66(24):11632-11643.
22. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A and Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. The Lancet Oncology. 2010; 11(4):339-349.
23. Granit RZ, Gabai Y, Hadar T, Karamansha Y, Liberman L, Waldhorn I, Gat-Viks I, Regev A, Maly B, Darash-Yahana M, Peretz T and Ben-Porath I. EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene. 2013; 32(33):3886-3895.
24. Lee J, Kim DH, Lee S, Yang QH, Lee DK, Lee SK, Roeder RG and Lee JW. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad SciUSA. 2009; 106(21):8513-8518.
25. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo JQ, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA, Watson MA, Saporita A, Weber JD, et al. PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer. Cancer Res. 2009; 69(9):3955-3962.
26. Copeland RA. Molecular pathways: protein methyltransferases in cancer. Clin Cancer Res. 2013; 19(23):6344-6350.
27. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R and Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet. 2013; 14(11):765-780.
28. Deb G, Thakur VS and Gupta S. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics. 2013; 8(5):464-476.
29. Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO, Stal O, Malmstrom P, Ferno M, Ryden L, Hegardt C, Borg A and Ringner M. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Molecular Oncol. 2012; 6(5):494-506.
30. Morishita M and di Luccio E. Cancers and the NSD family of histone lysine methyltransferases. Biochim Biophys Acta. 2011; 1816(2):158-163.
31. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L and Depinho RA. High-resolution genomic profiles of human lung cancer. Proc Natl Acad SciUSA. 2005; 102(27):9625-9630.
32. Rosati R, La Starza R, Veronese A, Aventin A, Schwienbacher C, Vallespi T, Negrini M, Martelli MF and Mecucci C. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood. 2002; 99(10):3857-3860.
33. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V and Pusztai L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009; 15(2):441-451.
34. Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Rouge C, Ursule L, Nguyen C, Bibeau F, Rodriguez C and Theillet C. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q. Br J Cancer. 2006; 95(10):1439-1447.
35. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F and Chaffanet M. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007; 67(24):11565-11575.
36. Rodriguez-Paredes M, Martinez de Paz A, Simo-Riudalbas L, Sayols S, Moutinho C, Moran S, Villanueva A, Vazquez-Cedeira M, Lazo PA, Carneiro F, Moura CS, Vieira J, Teixeira MR and Esteller M. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene. 2014; 33(21):2807-2813.
37. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, Gudjonsson S, Liedberg F, Patschan O, Mansson W, Ferno M and Hoglund M. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One. 2012; 7(6):e38863.
38. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferre F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011; 471(7339):513-517.
39. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T and Berger SL. Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006; 444(7119):629-632.
40. Saddic LA, West LE, Aslanian A, Yates JR, 3rd, Rubin SM, Gozani O and Sage J. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem. 2010; 285(48):37733-37740.
41. Zhang X, Tanaka K, Yan J, Li J, Peng D, Jiang Y, Yang Z, Barton MC, Wen H and Shi X. Regulation of estrogen receptor alpha by histone methyltransferase SMYD2-mediated protein methylation. Proc Natl Acad SciUSA. 2013; 110(43):17284-17289.
42. Wu J, Cheung T, Grande C, Ferguson AD, Zhu X, Theriault K, Code E, Birr C, Keen N and Chen H. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase. Biochemistry. 2011; 50(29):6488-6497.
43. Kim H, Heo K, Kim JH, Kim K, Choi J and An W. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol Chem. 2009; 284(30):19867-19877.
44. Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014; 510(7504):283-287.
45. Gregory GD, Vakoc CR, Rozovskaia T, Zheng X, Patel S, Nakamura T, Canaani E and Blobel GA. Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. Mol Cell Biol. 2007; 27(24):8466-8479.
46. Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB, Sun H, Kim JH, Carver K, Zucca M, Feng J, Almendro V, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014; 25(6):762-777.
47. Sun XJ, Xu PF, Zhou T, Hu M, Fu CT, Zhang Y, Jin Y, Chen Y, Chen SJ, Huang QH, Liu TX and Chen Z. Genome-wide survey and developmental expression mapping of zebrafish SET domain-containing genes. PLoS One. 2008; 3(1):e1499.
48. Fumasoni I, Meani N, Rambaldi D, Scafetta G, Alcalay M and Ciccarelli FD. Family expansion and gene rearrangements contributed to the functional specialization of PRDM genes in vertebrates. BMC Evolutionary Biol. 2007; 7:187.
49. Falandry C, Fourel G, Galy V, Ristriani T, Horard B, Bensimon E, Salles G, Gilson E and Magdinier F. CLLD8/KMT1F Is a Lysine Methyltransferase That Is Important for Chromosome Segregation. J Biol Chem. 2010; 285(26):20234-20241.
50. Botuyan MV, Lee J, Ward IM, Kim JE, Thompson JR, Chen J and Mer G. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell. 2006; 127(7):1361-1373.
51. Huang Y, Fang J, Bedford MT, Zhang Y and Xu RM. Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. Science. 2006; 312(5774):748-751.
52. Lee J, Thompson JR, Botuyan MV and Mer G. Distinct binding modes specify the recognition of methylated histones H3K4 and H4K20 by JMJD2A-tudor. Nat Struct Mol Biol. 2008; 15(1):109-111.
53. Ballabio E and Milne TA. Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. Cancers (Basel). 2012; 4(3):904-944.
54. Hu DQ, Gao X, Morgan MA, Herz HM, Smith ER and Shilatifard A. The MLL3/MLL4 Branches of the COMPASS Family Function as Major Histone H3K4 Monomethylases at Enhancers. Mol Cell Biol. 2013; 33(23):4745-4754.
55. Herz HM, Hu DQ and Shilatifard A. Enhancer Malfunction in Cancer. Mol Cell. 2014; 53(6):859-866.
56. Lee J, Kim DH, Lee S, Yang QH, Lee DK, Lee SK, Roeder RG and Lee JW. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad SciUSA. 2009; 106(21):8513-8518.
57. Copeland RA, Moyer MP and Richon VM. Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene. 2013; 32(8):939-946.
58. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP and Ethier SP. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer. 1999; 81(8):1328-1334.